Clinical trials located in


Chemnitz city is located in Germany. Currently, 20 clinical trials are being conducted in this city.

Chemnitz, located in eastern Germany, is renowned for its rich industrial heritage, particularly in mechanical engineering and automotive industries. The city’s landscape is marked by the Karl Marx Monument, a colossal bust of the philosopher, reflecting its historical ties to socialism. Chemnitz also boasts a vibrant cultural scene, with the Gunzenhauser Museum housing a significant collection of modern art. The city’s transformation from an industrial hub to a center of innovation and culture is encapsulated in its bid for the European Capital of Culture 2025.

  • CT-EU-00120826

    Study on the use of Volixibat for the treatment of pruritus in patients with primary cholangitis (PBC)

    The purpose of this clinical trial is to evaluate the efficacy and safety of an investigational drug called volixibat in patients with pruritus caused by primary cholangitis. The study aims to understand how volixibat affects the treatment of pruritus associated with this disease and to evaluate its possible effect on disease progression.

    Study participants will be randomly assigned to a group receiving volixibat or placebo. Volixibat will be administered as oral capsules twice daily. The main goal of the study is to measure the average change in daily pruritus scores using a special Adult Itch Reported Outcome (Adult ItchRO) questionnaire. Adult ItchRO is an 11-point scale for assessing pruritus severity, where 0 means no pruritus and 10 means the worst possible pruritus. The study will run from baseline to week 28.

    • Volixibat
    • Placebo
  • Study Comparing Asciminib and Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia

    This study examines the effects and tolerance of two drugs, asciminib and nilotinib, for treating a specific type of leukemia called Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in its chronic phase. The participants are adults who have been newly diagnosed and have not received previous treatment for this condition. They will be randomly assigned to receive either asciminib or nilotinib. The study aims to see which drug is better tolerated and how effective they are. Throughout the study, participants will be monitored for any side effects and the progress of their treatment until they either experience significant side effects, the disease progresses, or they decide to stop the treatment. Follow-up checks will also be conducted after the treatment ends.

    • Asciminib
    • Nilotinib
  • New therapy trial for relapsed large B-cell lymphoma

    This study is testing the use of two different treatments for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Group One receives a mix of drugs, including polatuzumab vedotin, rituximab, ifosfamide, carboplatin, and etoposide (collectively called Pola-R-ICE). Group Two receives a similar mix without polatuzumab vedotin, known as R-ICE. Patients will be randomly sorted into the two groups. The test treatment spans three months and includes three chemotherapy treatments. After that, doctors will follow up with patients for at least 21 months. The goal is to compare how well the two treatments work to control DLBCL. Different factors, like progress of the disease, the response to treatment, and overall health will be observed to determine how efficient these treatments are.

    • Mabthera
    • Ifosfamide
    • Polatuzumab vedotin
    • Etoposide
    • Carboplatin
  • Testing zimberelimab and domvanalimab with chemotheraphy for lung cancer

    This clinical trial explores the effectiveness of two new medicines, zimberelimab and domvanalimab, in tandem with chemotherapy for patients with untreated metastatic non-small cell lung cancer. The study’s main goal is to compare the impact and success of this combination treatment versus a control group receiving pembrolizumab along with chemotherapy. The hopeful outcome of the trial is to identify whether the new combination of drugs can provide enhanced benefits for the involved patients. Regular health monitoring will occur during the trial to ensure patient safety.

    • Pemetrexed
    • Nab-paclitaxel
    • Paclitaxel
    • Cisplatin
    • Carboplatin
    • Pembrolizumab
    • Domvanalimab
    • Zimberelimab
  • R-Pola-Glo therapy for aggressive B-cell lymphoma

    This clinical study tests a new treatment combination called R-Pola-Glo for elderly or medically unfit patients with untreated aggressive B-cell lymphoma. It involves the anti-CD20 antibody rituximab with polatuzumab vedotin and glofitamab, aiming to develop a less intense chemotherapy option. The trial, enrolling 80 participants, will assess the effectiveness and safety of this therapy, which could be crucial for those ineligible for standard treatment due to age or health.

    • Polatuzumab vedotin
    • Obinutuzumab
    • Glofitamab
    • Rituximab
  • Durvalumab and chemotherapy in advanced biliary tract cancer treatment

    This study is testing the effectiveness and safety of durvalumab, a biological drug, combined with various gemcitabine-based chemotherapy regimens in patients with advanced biliary tract cancers (aBTC). The trial will include four periods: a screening phase, a treatment phase of up to 8 cycles of chemotherapy with durvalumab, a maintenance phase with durvalumab alone or in combination with chemotherapy, and a follow-up phase for safety and survival. Patients will receive durvalumab via intravenous infusion every 3 or 4 weeks, along with chemotherapy every 3 or 2 weeks for a maximum of 8 cycles. The study’s primary goal is to observe any severe adverse events possibly related to the treatment. Secondary goals include measuring overall survival, response rate, progression-free survival, and other factors.

    • Gimeracil
    • Oteracil
    • Tegafur
    • Gemcitabine
    • Cisplatin
    • Carboplatin
    • Nab-paclitaxel
    • Oxaliplatin
    • Durvalumab
  • Examining ultrasound-assisted and standard treatment for lung clots

    In this study, researchers want to compare two treatments for a disease called pulmonary embolism. This is a disease in which a blood clot blocks the vessels that supply blood to the lungs. The group of people taking part in the study will be randomly assigned to receive either blood-thinning medications alone (anticoagulation) or blood-thinning medications using a blood clot-dissolving device. The name of this device is the EkoSonic endovascular device. The research will continue for 12 months, and the health of the participants will be regularly monitored.

    • Anticoagulation with heparin
  • Testing ravulizumab for transplant-related blood complications

    The study is examining a drug called ravulizumab used in adults and teenagers with a blood vessel disease called thrombotic microangiopathy (TMA) after a bone marrow transplant. Sometimes, new cells growing after a bone marrow transplant can cause problems in the blood vessels leading to TMA. So this study will investigate whether ravulizumab can help in this situation. In the first stage, each participant will receive the drug to determine the best dose. In the second phase, some will receive ravulizumab and best supportive care, while others will receive placebo and best supportive care. After 26 weeks of treatment, doctors will continue to monitor and record the patients’ health for another 26 weeks. Special blood tests will be done to check if the medicine is working.

    • Ravulizumab
  • Testing navitoclax and ruxolitinib effective on myelofibrosis patients

    This study is trying to find out if the combination of two drugs called Navitoclax and Ruxolitinib can help people with a type of blood cancer called Myelofibrosis. Around 330 adults, who have myelofibrosis that hasn’t responded to previous treatments, will get either the new drug combination or the current best treatment for their disease. Doctors will measure whether the new combination is more effective by checking how much the size of participants’ spleens have changed during the study with scans, measuring fatigue levels and checking how well their bone marrow works.

    • Navitoclax
    • Ruxolitinib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • A study of lanifibranor treatment in adults with nonalcoholic fatty liver disease

    This study is a two-part trial looking at how well a drug called Lanifibranor works for adults suffering from liver diseases known as NASH and fibrosis stages F2 and F3. In the first part of the trial, the researchers will compare the effects of Lanifibranor with a placebo, which is a substance with no medical effect. The researchers will be looking at how much the drug can improve the health of the liver. The second part of the study will continue the use of Lanifibranor to see if there are any long-term safety issues. Apart from studying the drug’s effectiveness in resolving NASH and reducing live fibrosis, the trial will also be observing how it affects other aspects of liver health, diabetes, blood sugar and fat levels, liver stiffness and patients’ quality of life.

    • Lanifibranor
  • Comparing atogepant and topiramate for migraine prevention

    In this study, a comparison is being made between two different medicines aimed at preventing migraines in adults. Migraines manifest as severe headaches on one side of the head, accompanied by symptoms such as nausea, throbbing pain, or sensitivity to light and sound. The two medicines under comparison are named atogepant and topiramate. Atogepant is currently employed for migraine prevention in individuals experiencing migraines from 0 to 14 days per month, and the study seeks to evaluate its potential broader application. Topiramate is already widely utilized for migraine prevention. Participants in this study will be divided into two groups: one group will be administered atogepant, while the other will receive topiramate for a duration of 24 weeks. Following this period, those eligible to continue will all receive atogepant for an additional 52 weeks. The study will assess their progress and monitor any potential side effects.

    • Topiramate
    • Atogepant
  • Study testing new chemotherapy combination for aggressive B-Cell Lymphoma treatment

    This study is for people over 60 who have never been treated for an aggressive type of blood cancer, called B-cell lymphoma, and who can’t receive the regular treatment, called R-CHOP. Instead of traditional chemotherapy, researchers will use the light treatment concept R-Pola-Glo that combines the anti-CD20 antibody rituximab (R) with the ADC polatuzumab vedotin (Pola) and the (BiMabs) glofitamab (Glo). The trial will look at factors like how long it takes for the disease to come back or get worse, the response rates after 2, 6, and 12 treatment cycles, and the percentage of people who experience side effects. It will also consider the effect on life quality, using two surveys designed by cancer research organizations.

    • Polatuzumab vedotin
    • Obinutuzumab
    • Glofitamab
    • Rituximab
  • Study on hepatocellular carcinoma treatment using transarterial chemoembolization and drug therapy

    This international study is testing new treatments for hepatocellular carcinoma. Patients will receive transarterial chemoembolization (TACE) or TACE combined with drugs like durvalumab, tremelimumab, and lenvatinib. The main objective is to assess the efficacy and safety of combining transarterial chemoembolization (TACE) with the immunotherapy drugs durvalumab and tremelimumab, and possibly drug lenvatinib. TACE involves injecting chemo and embolic agents directly into the liver’s blood vessels. The new drug combination is given through IV and pills. The main goal is to see if adding these drugs to TACE helps slow down cancer progression and improves survival.

    • Lenvatinib
    • Tremelimumab
    • Durvalumab
  • Study of savolitinib and osimertinib Vs chemotherapy in advancing lung cancer

    This clinical trial will include approximately 324 people with a specific type of advanced lung cancer that has not improved with a specific treatment, osimertinib. People in this study will receive a combination of two drugs, savolitinib and osimertinib, or standard chemotherapy. The aim is to find out which treatment is more effective and safe. A person’s cancer will be monitored to see how it responds to treatment. If the cancer gets worse or the side effects become too much to bear, the person may stop participating in the study. The study will measure responses such as the number of people who see improvement in their cancer treatment, the time it takes for symptoms to get worse and the presence of drugs in the body.

    • savolitinib
    • Osimertinib
    • Pemetrexed
    • Cisplatin
    • Carboplatin
  • Study of the effects of Durvalumab and Domvanalimab on non-small cell lung cancer

    This study looks at two drugs – Durvalumab and Domvanalimab – and how they may help people with a type of lung cancer that cannot be removed by surgery. These medicines are given to patients after special treatment combining chemotherapy and radiotherapy. The goal is to find out whether these drugs provide benefits and are safe to use. During the trial, patients will be given the real drug or a placebo (a substance that has no therapeutic effect), without knowing which one they will receive. The study will measure how long it takes for the disease to worsen, how long people live and how many people respond positively to treatment. This clinical trial is testing the effectiveness of Durvalumab and Domvanalimab – two drugs – in the treatment of stage III lung cancer that cannot be surgically removed. After undergoing chemotherapy and radiation therapy, participants will be given these drugs to assess their safety. The study is double-blind, meaning neither participants nor researchers know who is receiving the actual drug and who is receiving the placebo. The study will monitor whether the cancer gets worse and what the rate of positive reactions to the drugs is. A study is being conducted with two drugs, Durvalumab and Domvanalimab, for patients with advanced forms of lung cancer that cannot be treated with surgery. After undergoing combined chemotherapy and radiation therapy, participants receive these drugs. The study was designed so that neither the patient nor the doctor knew whether the correct drug or a placebo was being administered. The time until the disease worsens, how long participants live and the number of patients who see improvement with the drugs will be measured.

    • Domvanalimab
    • Durvalumab
  • Drug study – AZD9833 in advanced HR+/HER2- breast cancer with ESR1 mutation

    The study focuses on advanced breast cancer, specifically hormone receptor-positive (HR-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) cases. These patients show an ESR1 gene mutation that might cause current treatments to stop working well. The body’s inability to control cell growth leads to tumors in the breast, and when these tumors spread to other parts of the body, it becomes advanced cancer.

    AZD9833, an unapproved trial drug, will be compared with two existing treatments: palbociclib, abemaciclib, and ribociclib (which block tumor growth), and letrozole and anastrozole (aromatase inhibitors, AI), to see if it works better when combined with palbociclib, abemaciclib, or ribociclib in patients with the ESR1 mutation.

    Participants will either continue their current combination of AI and CDK4/6 inhibitor or switch to AZD9833 and a CDK4/6 inhibitor. The goal is to see which combination is better at extending the time before the cancer gets worse and to learn more about AZD9833’s safety.

    Participants in this trial will have been receiving combinations of an AI and a CDK4/6 inhibitor beforehand. During the trial, they will remain on the same CDK4/6 inhibitor.

    Participants will be split into two groups: Group A will receive AZD9833, a CDK4/6 inhibitor, and a placebo. Group B will receive an AI, a CDK4/6 inhibitor, and a placebo.

    The treatments will be taken daily in 28-day cycles as follows: either AZD9833 or an AI plus the placebo. If taking abemaciclib: twice daily for 28 days. If taking palbociclib or ribociclib: once daily for 21 days, followed by a 7-day break. This 28-day cycle will repeat for the duration of participation in the trial.

    • Camizestrant
    • Luteinizing hormone-releasing hormone (LHRH) agonist
    • Abemaciclib
    • Palbociclib
    • Ribociclib
    • Anastrozole
    • Letrozole
  • Study of a new drug combination for treating aggressive B-cell lymphoma

    This trial examines a new therapy for elderly patients with a severe type of blood cancer, called aggressive large B-cell lymphoma, who cannot undergo standard treatment. Known as the R-Pola-Glo treatment, it combines three drugs: rituximab, polatuzumab vedotin, and glofitamab. About 80 participants will be involved. The study will observe how well this combination works and monitor any side effects. It aims to improve treatment options for patients who need an alternative to the usual therapy.

    • Polatuzumab vedotin
    • Obinutuzumab
    • Glofitamab
    • Rituximab
  • Evaluating a new treatment for challenging solid tumors in a multi-stage trial

    In the IMA402 study, doctors want to test a new treatment for patients with solid tumors that haven’t responded to other treatments or have returned. The treatment involves a drug called IMA402 that focuses on PRAME, a molecule that is often seen in these types of cancers. The study aims to understand the safest and highest amount of IMA402 that can be safely given to patients (Phase I) and also to discover whether this treatment can effectively fight against cancer (Phase II). To better understand how the drug impacts patients, the trial is split into three stages with varying doses. The goal is to eventually find a dose that can help patients with hard-to-treat solid tumors.

    • IMA402

See more clinical trials in other cities in Germany: